Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/58969
Title: Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer
Authors: Ekkasit Tharavichitkul
Somvilai Chakrabandhu
Pitchayaponne Klunklin
Wimrak Onchan
Bongkot Jia-Mahasap
Somsak Wanwilairat
Damrongsak Tippanya
Rungtip Jayasvasti
Patumrat Sripan
Razvan M. Galalae
Imjai Chitapanarux
Keywords: Medicine
Issue Date: 1-Mar-2018
Abstract: © 2018 Objectives: To report the intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer. Materials and methods: Ninety-two patients with cervical cancer (stage IB-IVA, according to FIGO staging), were treated by curative radiotherapy from February 2012 to June 2015. All patients were treated with whole pelvic radiotherapy to 50 Gy in 25 fractions and central shielding after 44 Gy, in combination with TAUS-guided brachytherapy, in order to escalate the total dose (EQD2) to the minimal dose at cervical points (in EQD2 concepts) defined by TAUS, while maintaining low doses to ICRU bladder and rectal points. The treatment results and toxicity profiles were reported. Results: At median follow-up time of 41.2 months (range 8 to 61 months) the pelvic control, disease-free survival, and overall survival rates were 84.8%, 75%, and 88%, respectively. The mean applied doses to cervix, bladder, and rectal points were 83.5, 72.3, and 76.5 Gy, respectively. Eight patients developed grade 2 Gastrointestinal toxicity. Conclusion: The 3-year results demonstrated that TAUS-guided brachytherapy is feasible and associated with excellent tumor control/toxicity rates in cervical cancer.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041595029&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/58969
ISSN: 10956859
00908258
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.